Andrzej S Krolewski

List of Publications by Year
in descending order

48 papers	6,106 citations	147801 31 h-index	233421 45 g-index
48 all docs	48 docs citations	48 times ranked	6169 citing authors

#	Article	IF	Citations
1	Results of untargeted analysis using the SOMAscan proteomics platform indicates novel associations of circulating proteins with risk of progression to kidney failure in diabetes. Kidney International, 2022, 102, 370-381.	5.2	17
2	A profile of multiple circulating tumor necrosis factor receptors associated with early progressive kidney decline in Type 1 Diabetes is similar to profiles in autoimmune disorders. Kidney International, 2021, 99, 725-736.	5.2	11
3	Effect of TNFÎ± stimulation on expression of kidney risk inflammatory proteins in human umbilical vein endothelial cells cultured in hyperglycemia. Scientific Reports, 2021, 11, 11133.	3.3	2
4	Circulating proteins protect against renal decline and progression to end-stage renal disease in patients with diabetes. Science Translational Medicine, 2021, 13, .	12.4	18
5	Comprehensive Search for Novel Circulating miRNAs and Axon Guidance Pathway Proteins Associated with Risk of ESKD in Diabetes. Journal of the American Society of Nephrology: JASN, 2021, 32, 2331-2351.	6.1	20
6	Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2021, 32, 2634-2651.	6.1	9
7	Profibrotic Circulating Proteins and Risk of Early Progressive Renal Decline in Patients With Type 2 Diabetes With and Without Albuminuria. Diabetes Care, 2020, 43, 2760-2767.	8.6	21
8	A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nature Medicine, 2019, 25, 805-813.	30.7	260
9	Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy. Diabetes Care, 2019, 42, 93-101.	8.6	37
10	Circulating miRNA Profiles Associated With Hyperglycemia in Patients With Type 1 Diabetes. Diabetes, 2018, 67, 1013-1023.	0.6	73
11	Markers of early progressive renal decline in typeÂ2Âdiabetes suggest different implications forÂetiological studies and prognostic testsÂdevelopment. Kidney International, 2018, 93, 1198-1206.	5.2	88
12	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.6	136
13	New Frontiers: Approaches to Understand the Mechanistic Basis of Renal Toxicity. Toxicologic Pathology, 2018, 46, 1002-1005.	1.8	0
14	Improved clinical trial enrollment criterion toÂidentify patients with diabetes at risk of end-stage renal disease. Kidney International, 2017, 92, 258-266.	5.2	38
15	Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney International, 2017, 91, 1300-1311.	5.2	159
16	The Genetic Landscape of Renal Complications in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2017, 28, 557-574.	6.1	101
17	Patterns of Estimated Glomerular Filtration Rate Decline Leading to End-Stage Renal Disease in Type 1 Diabetes. Diabetes Care, 2016, 39, 2262-2269.	8.6	46
18	Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney International, 2016, 89, 226-234.	5.2	57

#	Article	IF	Citations
19	Differential Gene Expression in Diabetic Nephropathy in Individuals With Type 1 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2015, 100, E876-E882.	3.6	18
20	Progressive Renal Decline: The New Paradigm of Diabetic Nephropathy in Type 1 Diabetes. Diabetes Care, 2015, 38, 954-962.	8.6	176
21	Cardiac Autonomic Neuropathy and Early Progressive Renal Decline in Patients with Nonmacroalbuminuric Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1136-1144.	4.5	41
22	Circulating TGF-Î²1â€“Regulated miRNAs and the Risk of Rapid Progression to ESRD in Type 1 Diabetes. Diabetes, 2015, 64, 3285-3293.	0.6	85
23	Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney International, 2015, 87, 812-819.	5.2	103
24	Improved Glycemic Control and Risk of ESRD in Patients with Type 1 Diabetes and Proteinuria. Journal of the American Society of Nephrology: JASN, 2014, 25, 2916-2925.	6.1	39
25	Synergism Between Circulating Tumor Necrosis Factor Receptor 2 and HbA1c in Determining Renal Decline During 5â€“18 Years of Follow-up in Patients With Type 1 Diabetes and Proteinuria. Diabetes Care, 2014, 37, 2601-2608.	8.6	43
26	Role of Podocyte B7-1 in Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1415-1429.	6.1	114
27	Early Progressive Renal Decline Precedes the Onset of Microalbuminuria and Its Progression to Macroalbuminuria. Diabetes Care, 2014, 37, 226-234.	8.6	219
28	Progressive renal decline as the major feature of diabetic nephropathy in type 1 diabetes. Clinical and Experimental Nephrology, 2014, 18, 571-583.	1.6	18
29	Blood Kidney Injury Molecule-1 Is a Biomarker of Acute and Chronic Kidney Injury and Predicts Progression to ESRD in Type I Diabetes. Journal of the American Society of Nephrology: JASN, 2014, 25, 2177-2186.	6.1	341
30	Uremic solutes and risk of end-stage renal disease in type 2 diabetes: metabolomic study. Kidney International, 2014, 85, 1214-1224.	5.2	182
31	Serum Concentration of Cystatin C and Risk of End-Stage Renal Disease in Diabetes. Diabetes Care, 2012, 35, 2311-2316.	8.6	61
32	The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end-stage renal disease. Kidney International, 2012, 82, 589-597.	5.2	120
33	Circulating TNF Receptors 1 and 2 Predict ESRD in Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 507-515.	6.1	388
34	High Risk of ESRD in Type 1 Diabetes: Call for Action: Introduction. Seminars in Nephrology, 2012, 32, 405-406.	1.6	4
35	Circulating TNF Receptors 1 and 2 Predict Stage 3 CKD in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 516-524.	6.1	307
36	Risk for ESRD in Type 1 Diabetes Remains High Despite Renoprotection. Journal of the American Society of Nephrology: JASN, 2011, 22, 545-553.	6.1	166

#	Article	IF	Citations
37	Four RSAI restriction fragment melting polymorphisms in the region of the insulin receptor gene encoding for the alpha subunit. Clinical Genetics, 2008, 44, 279-280.	2.0	1
38	High-Normal Serum Uric Acid Is Associated with Impaired Glomerular Filtration Rate in Nonproteinuric Patients with Type 1 Diabetes. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 706-713.	4.5	130
39	Microalbuminuria and the Risk for Early Progressive Renal Function Decline in Type 1 Diabetes. Journal of the American Society of Nephrology: JASN, 2007, 18, 1353-1361.	6.1	325
40	A database of naturally occurring human urinary peptides and proteins for use in clinical applications. Nature Precedings, 2007, , .	0.1	0
41	Regression of Microalbuminuria in Type 1 Diabetes. New England Journal of Medicine, 2003, 348, 2285-2293.	27.0	719
42	Mutation Screening of the Neurogenin-3 Gene in Autosomal Dominant Diabetes1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2320-2322.	3.6	9
43	Mutations in NEUROD1 are associated with the development of type 2 diabetes mellitus. Nature Genetics, 1999, 23, 323-328.	21.4	551
44	Ticlopidine May Reduce Functional Fibrinogen Levels by Inhibition of MPC Incorporation into Fibrin. Thrombosis and Haemostasis, 1997, 77, 603-604.	3.4	1
45	Genetic susceptibility to nephropathy in insulinâ€dependent diabetes: From epidemiology to molecular genetics. Diabetes/metabolism Reviews, 1995, 11, 287-314.	0.3	48
46	Molecular characterization of a DDEI melting polymorphism at the angiotensin I-converting enzyme (ACE) locus. Human Mutation, 1994, 4, 155-157.	2.5	6
47	Comments on Plasma Fibrinogen Levels Measured by Functional Methods. Thrombosis and Haemostasis, 1994, 72, 985-985.	3.4	3
48	The changing natural history of nephropathy in type I Diabetes. American Journal of Medicine, 1985, 78, 785-794.	1.5	795